Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Yuming Luo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-7145-5470; OpenAlex author ID A5076793468. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 13

  1. Correction: circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Co-author DOI 10.1186/s12943-026-02730-6↗
  2. Endosomal Trafficking Bypassed by the RAB5B-CD109 Interplay Promotes Axonogenesis in KRAS-Mutant Pancreatic Cancer. First author DOI 10.1002/advs.202405092↗
  3. Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/0008-5472.can-22-3997↗
  4. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer. Co-author DOI 10.1186/s13046-023-02854-3↗
  5. Corrigendum to "Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in … Co-author DOI 10.1016/j.canlet.2022.215859↗
  6. KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer. Co-author DOI 10.1172/jci157644↗
  7. Correction: lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Co-author DOI 10.1186/s12943-022-01585-x↗
  8. lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Co-author DOI 10.1186/s12943-020-01153-1↗
  9. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis. Co-author DOI 10.1186/s12943-020-01196-4↗
  10. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Co-author DOI 10.1186/s12943-020-01205-6↗
  11. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.13351↗
  12. Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Co-author DOI 10.1038/cddiscovery.2017.4↗
  13. Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-rela… Co-author DOI 10.1016/j.canlet.2015.12.010↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changhao Chen · 8 shared papers, 2020–2026 · strength 1.24
  2. Shangyou Zheng · 8 shared papers, 2016–2023 · strength 0.87
  3. Yao Kong · 5 shared papers, 2020–2026 · strength 0.80
  4. Rufu Chen · 4 shared papers, 2020–2026 · strength 0.69
  5. Zhiqiang Fu · 7 shared papers, 2016–2023 · strength 0.69
  6. Rufu Chen · 4 shared papers, 2020–2024 · strength 0.56
  7. Xiaofeng Guo · 3 shared papers, 2020–2026 · strength 0.50
  8. Zhihua Li · 3 shared papers, 2020–2026 · strength 0.50
  9. Jiabin Yang · 3 shared papers, 2022–2024 · strength 0.49
  10. Dingwen Zhang · 3 shared papers, 2022–2024 · strength 0.49
  11. Huilin Ye · 5 shared papers, 2016–2022 · strength 0.48
  12. Zhihua Li · 4 shared papers, 2016–2022 · strength 0.38
  13. Quanbo Zhou · 4 shared papers, 2016–2022 · strength 0.33
  14. Xiaohui Zhao · 4 shared papers, 2016–2022 · strength 0.30
  15. Yimin Liu · 4 shared papers, 2016–2022 · strength 0.30
  16. Y P. Li · 1 shared paper, 2026 · strength 0.29
  17. Rufu Chen · 3 shared papers, 2016–2022 · strength 0.25
  18. Xiaofan Ren · 2 shared papers, 2020–2022 · strength 0.25
  19. Mingyang Liu · 2 shared papers, 2020–2022 · strength 0.25
  20. Wenzhu Li · 3 shared papers, 2016–2022 · strength 0.24
  21. Yingxue Wang · 3 shared papers, 2016–2022 · strength 0.23
  22. Zhuo Kui Wu · 1 shared paper, 2024 · strength 0.19
  23. Chao Yu · 1 shared paper, 2024 · strength 0.19
  24. Min Yu · 1 shared paper, 2024 · strength 0.19
  25. Zhou Fang · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.